Upstate Active Clinical Trials

Study Title:

PrE1702- Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/- Chemotherapy) for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients

What is the purpose of the study? (in Layman's terms, please describe the study)

Non-Interventional Study. Treating physician determines whether patient will receive single agent osimertinib or osimertinib with chemotherapy and the planned treatment is recorded at registration.

Upstate Institutional Review Board (IRB) Number:

22324280

Study/Protocol ID:

Pre1702

Study Phase:

Registry

Patient Age Group:

Adults

Principal Investigator:

Stephen L Graziano, MD

Who is eligible?

Patient tumor must have somatic activating sensitizing mutation in EGFR (e.g., but not limited to Exon 19 deletion, L858R, E709X, G719X, exon 19 insertions, L861Q, S768I). Patients with non-sensitizing mutations in EGFR (EGFR exon 20 insertions) are not eligible. Plasma, cytology, or tumor tissue can be utilized for standard of care mutation testing.

What is involved if I participate?

• How long is the study?
  10/y
• Is transportation provided or reimbursed?
  No
• Is parking provided or reimbursed?
  No
• What tests and procedures are involved?
  No tests involved this is a registry

Where will the study take place?

Cancer Center-Oswego-Verona -Communtiy

Other Information:

N/A

Who can I contact for more information?

Name: Raneem Alarawi
Phone: 315-464-6074
Email: [email protected]

Return to Previous Page || Search Again